Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Never miss an Options trading signal: Unusual Options Activity and Options Screeners with Barchart Premier. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or
Faster, Cleaner, Better.

Denali Therapeutics Inc (DNLI)

Denali Therapeutics Inc (DNLI)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]] ([[ financialData.relativeStrengthDirection14d ]]) ([[ financialData.highPercent1y ]]) ([[ financialData.lowPercent1y ]])
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 3,262,217
  • Shares Outstanding, K 158,591
  • Annual Sales, $ 0 K
  • Annual Income, $ -512,540 K
  • EBIT $ -555 M
  • EBITDA $ -554 M
  • 60-Month Beta 1.10
  • Price/Sales N/A
  • Price/Cash Flow N/A
  • Price/Book 3.00

Options Overview Details

View History
  • Implied Volatility 68.85% (+2.02%)
  • Historical Volatility 71.23%
  • IV Percentile 12%
  • IV Rank 14.26%
  • IV High 155.38% on 11/13/25
  • IV Low 54.46% on 08/18/25
  • Expected Move (DTE 25) 0.60 (2.89%)
  • Put/Call Vol Ratio 0.10
  • Today's Volume 325
  • Volume Avg (30-Day) 977
  • Put/Call OI Ratio 0.53
  • Today's Open Interest 13,894
  • Open Int (30-Day) 13,273
  • Expected Range 19.98 to 21.17

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 19 analysts offering recommendations.
Earnings Estimates - Current Qtr 03/31/26
See More
  • Average Estimate $-0.73
  • Number of Estimates 10
  • High Estimate $-0.54
  • Low Estimate $-0.86
  • Prior Year $-0.78
  • Growth Rate Est. (year over year) +6.41%

Price Performance

See More
Period Period Low Period High Performance
1-Month
17.86 +15.17%
on 03/30/26
23.46 -12.32%
on 03/25/26
-0.14 (-0.68%)
since 03/17/26
3-Month
17.18 +19.73%
on 01/20/26
23.77 -13.46%
on 02/03/26
+2.58 (+14.34%)
since 01/16/26
52-Week
12.31 +67.10%
on 04/21/25
23.77 -13.46%
on 02/03/26
+7.83 (+61.46%)
since 04/17/25

Most Recent Stories

More News
Denali Therapeutics Regains Full Rights to Investigational Therapy DNL593 (PTV:PGRN) for GRN-related Frontotemporal Dementia (FTD-GRN)

Denali plans to continue clinical development of DNL593, which is designed to deliver progranulin to the brain using TransportVehicle™ technology Results from ongoing Phase 1/2 study in patients with...

DNLI : 20.57 (-0.68%)
Denali Therapeutics Announces U.S. FDA Approval of AVLAYAH™ (tividenofusp alfa-eknm) for Treatment of Hunter Syndrome (MPS II)

First new FDA-approved treatment option in nearly 20 years for families living with this rare lysosomal storage disease First FDA-approved medicine in emerging new class of biotherapeutics that leverage...

DNLI : 20.57 (-0.68%)
Denali Therapeutics Announces U.S. FDA Approval of AVLAYAH™ (tividenofusp alfa-eknm) for Treatment of Hunter Syndrome (MPS II)

First new FDA-approved treatment option in nearly 20 years for families living with this rare lysosomal storage disease First FDA-approved medicine in emerging new class of biotherapeutics that leverage...

DNLI : 20.57 (-0.68%)
Denali Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Business Highlights

Tividenofusp alfa (DNL310; ETV:IDS) launch readiness established ahead of April 5, 2026 Prescription Drug User Fee Act (PDUFA) target action date for Hunter syndrome DNL126 (ETV:SGSH) Phase 1/2 preliminary...

DNLI : 20.57 (-0.68%)
Denali Therapeutics Presents Enzyme TransportVehicle™ Progress Across Three Clinical Programs for Treatment of Lysosomal Storage Disorders at 2026 WORLDSymposium™

Analysis from continued follow-up of Phase 1/2 clinical trial data in Hunter syndrome (MPS II) reinforces potential for tividenofusp alfa (DNL310) to address full disease spectrum Launch readiness established...

DNLI : 20.57 (-0.68%)
Denali Therapeutics To Host Webcast Highlighting Presentations on Enzyme TransportVehicle™ Programs at the 2026 WORLDSymposium™

SOUTH SAN FRANCISCO, Calif., Feb. 02, 2026 (GLOBE NEWSWIRE) -- Denali Therapeutics Inc. (Nasdaq: DNLI) today announced that management will host a live webcast to review presentations on its Enzyme TransportVehicle™...

DNLI : 20.57 (-0.68%)
Denali Therapeutics Announces Data Presentations on Enzyme TransportVehicle™ Programs for Hunter Syndrome, Sanfilippo Syndrome Type A and Pompe Disease at Upcoming 2026 WORLDSymposium™

Hunter syndrome (MPS II) presentations will include analysis from continued follow-up of Phase 1/2 data for tividenofusp alfa (DNL310), currently under FDA Priority Review Preliminary data from Phase...

DNLI : 20.57 (-0.68%)
Denali Therapeutics Announces Key Anticipated Milestones and Priorities for 2026 Including Commercial Launch of Tividenofusp Alfa for Hunter Syndrome

Preparing for FDA approval and commercial launch of tividenofusp alfa, Denali’s TransportVehicle™ (TV)-enabled investigational therapy for Hunter syndrome Expecting multiple clinical data readouts...

DNLI : 20.57 (-0.68%)
The New England Journal of Medicine Publishes Phase 1/2 Study of Denali Therapeutics’ Tividenofusp Alfa (DNL310) for Hunter Syndrome (MPS II)

Tividenofusp alfa treatment showed reduction and normalization in key disease biomarkers, stabilization or improvement in clinical endpoints including adaptive behavior, cognition and hearing, and normalization...

DNLI : 20.57 (-0.68%)
Beyond Weight Loss: The "Cellular Reset" That Could Create the Next Biotech Supercycle

Issued on behalf of Avant Technologies Inc. VANCOUVER – Baystreet.ca News Commentary – The longevity economy is entering a massive repricing event as researchers confirm that metabolic dysfunction...

LGVN : 1.1000 (unch)
AVAI : 0.3158 (-1.31%)
BIOA : 18.49 (+8.83%)
GAA : 34.98 (+1.03%)
DNLI : 20.57 (-0.68%)
MAPT : 0.0003 (+50.00%)
KLTO : 0.5242 (+0.81%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 80% Buy with a Weakening short term outlook on maintaining the current direction.

Long term indicators fully support a continuation of the trend.

See More Share

Business Summary

Denali Therapeutics, a biopharmaceutical company, is developing a wide and innovative portfolio of targeted therapeutic candidates, which are engineered to cross the blood-brain barrier for neurodegenerative diseases. It has 5 clinical-stage programs, a leucine-rich repeat kinase 2 inhibitor program...

See More

Key Turning Points

3rd Resistance Point 21.94
2nd Resistance Point 21.66
1st Resistance Point 21.11
Last Price 20.57
1st Support Level 20.28
2nd Support Level 20.00
3rd Support Level 19.45

See More

52-Week High 23.77
Last Price 20.57
Fibonacci 61.8% 19.39
Fibonacci 50% 18.04
Fibonacci 38.2% 16.69
52-Week Low 12.31

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.